Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.56 |
| ▸ | TSHR | P16473 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21430923 | 0.84 | LMNA (0.72) | HPGDSMN1; SMN2HTTKDM4EALDH1A1 | |
| SCHEMBL899121 | 0.83 | TGM2 (0.52) | HPGDSMN1; SMN2HTTKDM4EPOLB | |
| SCHEMBL4341926 | 0.82 | KMT2A (0.71) | HPGDSMN1; SMN2HTTKMT2AKDM4E | |
| SCHEMBL24594132 | 0.82 | SMN1; SMN2 (0.75) | HPGDSMN1; SMN2HTTKMT2AKDM4E | |
| SCHEMBL3071834 | 0.82 | LMNA (0.74) | HPGDSMN1; SMN2HTTKMT2AKDM4E | |
| SCHEMBL29367186 | 0.81 | TGM2 (0.58) | HPGDSMN1; SMN2KMT2AKDM4EPOLB | |
| SCHEMBL890714 | 0.81 | TGM2 (0.58) | HPGDSMN1; SMN2KMT2AKDM4EPOLB | |
| SCHEMBL10965735 | 0.81 | KMT2A (0.69) | HPGDSMN1; SMN2HTTKMT2AKDM4E | |
| SCHEMBL3265331 | 0.81 | CA12 (0.56) | HPGDSMN1; SMN2HTTKMT2AKDM4E | |
| SCHEMBL15619558 | 0.81 | HPGD (0.78) | HPGDSMN1; SMN2HTTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051638-A1 | POWDERED FLUOROCHROME COMPOSITION, RESIN COMPOSITION, MOLDED ARTICLE, AND METHOD FOR PRODUCING POWDERED FLUOROCHROME COMPOSITION | DIC CORPORATION (JP) | 2025-02-13 | — | — | US | disclosed |
| CN-118434822-A | Powdery pigment composition, method for producing powdery pigment composition, resin composition, and molded article | DIC株式会社 | 2024-08-02 | — | — | CN | disclosed |
| CN-114728910-B | Pyrazole derivative for FGFR inhibitor and preparation method thereof | 上海奕拓医药科技有限责任公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20220298143-A1 | Pyrazole Derivatives for FGFR Inhibitor and Preparation Method Thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2022-09-22 | — | — | US | disclosed |
| CN-114728910-A | Pyrazole derivatives for FGFR inhibitor and preparation method thereof | 上海奕拓医药科技有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4023639-A1 | PYRAZOLE DERIVATIVE FOR FGFR INHIBITOR AND PREPARATION METHOD THEREFOR | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2022-07-06 | — | — | EP | disclosed |
| CN-113248399-A | O-amino aromatic amide derivative and preparation method and application thereof | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 2021-08-13 | — | — | CN | disclosed |
| WO-2021037219-A1 | PYRAZOLE DERIVATIVE FOR FGFR INHIBITOR AND PREPARATION METHOD THEREFOR | 上海奕拓医药科技有限责任公司 | 2021-03-04 | — | — | WO | disclosed |
| WO-2021037219-A1 | PYRAZOLE DERIVATIVE FOR FGFR INHIBITOR AND PREPARATION METHOD THEREFOR | 上海奕拓医药科技有限责任公司 | 2021-03-04 | — | — | WO | disclosed |
| WO-2008069611-A1 | N-PHENYLAMIDE DERIVATIVE, PROCESS FOR THE PREPARATION THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING ISCHEMIC DISEASES COMPRISING SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-06-12 | — | — | WO | disclosed |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | GPR119, FFAR1, HCAR1 | HPGD 180/4885SMN1; SMN2 3471/4885HTT 1802/4885 |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | LDLR, APOB, FFAR1 | HPGD 218/4885SMN1; SMN2 2600/4885HTT 1412/4885 |
| US-20220298143-A1 | Pyrazole Derivatives for FGFR Inhibitor and Preparation Method Thereof | FGFR1, FGFR2, FGFR3 | HPGD 933/4885SMN1; SMN2 4532/4885HTT 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.